0.00Open0.00Pre Close0 Volume0 Open Interest9.00Strike Price0.00Turnover235.51%IV-121.13%PremiumDec 20, 2024Expiry Date4.93Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8237Delta0.1024Gamma0.80Leverage Ratio-0.0118Theta-0.0044Rho-0.66Eff Leverage0.0029Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet